Skip to main content

Nabriva Therapeutics PLC (NBRV)

NASDAQ: NBRV · IEX Real-Time Price · USD
1.10
+0.01 (0.92%)
After-hours:Oct 22, 2021 7:36 PM EDT
1.09
-0.04 (-3.11%)
At close: Oct 22, 4:00 PM
Market Cap55.16M
Revenue (ttm)14.52M
Net Income (ttm)-56.52M
Shares Out50.37M
EPS (ttm)-2.31
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume569,878
Open1.12
Previous Close1.13
Day's Range1.06 - 1.12
52-Week Range1.00 - 5.70
Beta1.69
AnalystsBuy
Price Target2.67 (+145.0%)
Est. Earnings DateNov 4, 2021

About NBRV

Nabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company's product includes XENLETA, a semi-synthetic pleuromutilin antibiotic for the treatment of community-acquired bacterial pneumonia; and SIVEXTRO, an oxazolidinone-class antibacterial for the treatment of acute bacterial skin and skin structure infection (ABSSSI). It also develops XENLETA that is in Phase I clinical trial for the treatment of pediatric infections, as well a...

IndustryPharmaceuticals
IPO DateSep 18, 2015
CEOTheodore Schroeder
Employees72
Stock ExchangeNASDAQ
Ticker SymbolNBRV
Full Company Profile

Financial Performance

In 2020, NBRV's revenue was $5.03 million, a decrease of -46.98% compared to the previous year's $9.48 million. Losses were -$69.48 million, -16.05% less than in 2019.

Financial Statements

Analyst Forecast

According to 4 analysts, the average rating for NBRV stock is "Buy." The 12-month stock price forecast is 2.67, which is an increase of 144.95% from the latest price.

Price Target
$2.67
(144.95% upside)
Analyst Consensus: Buy

News

Nabriva Therapeutics to Present Data at CHEST Annual Meeting 2021

DUBLIN, Ireland and FORT WASHINGTON, Pa., Oct. 15, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innov...

1 week ago - GlobeNewsWire

Nabriva Publishes Data Demonstrating the Potent Anti-Inflammatory Properties of XENLETA® (lefamulin)

DUBLIN, Ireland and FORT WASHINGTON, Pa., Oct. 04, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innov...

2 weeks ago - GlobeNewsWire

Nabriva Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

DUBLIN, Ireland, Oct. 01, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agen...

3 weeks ago - GlobeNewsWire

Nabriva Therapeutics Appoints Dr. Christine Guico-Pabia, M.D., as Chief Medical Officer

DUBLIN, Ireland and FORT WASHINGTON, Pa., Oct. 01, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innov...

3 weeks ago - GlobeNewsWire

Antimicrobials Working Group Highlights Member Company Participation at IDWeek 2021

WASHINGTON, Sept. 30, 2021 /PRNewswire/ -- The Antimicrobials Working Group (AWG), a coalition of companies with the mission to combat drug resistant infections and spur life-saving innovations, today a...

3 weeks ago - PRNewsWire

Nabriva Therapeutics to Present Data at IDWeek 2021

DUBLIN, Ireland and FORT WASHINGTON, Pa., Sept. 24, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of inno...

4 weeks ago - GlobeNewsWire

Nabriva Therapeutics, Vizient Inks Xenleta Distribution Pact

Nabriva Therapeutics Plc (NASDAQ: NBRV) entered an agreement with Vizient to offer Xenleta as a contracted product to Vizient's Pharmacy Network Program. Xenleta is indicated for community-acquired bact...

1 month ago - Benzinga

Nabriva and Vizient Enter into Agreement to Make XENLETA® (lefamulin) Available to Vizient's Pharmacy Network Program

- Expands access to XENLETA for hospitalized patients with Community Acquired Bacterial Pneumonia (CABP) - Expands access to XENLETA for hospitalized patients with Community Acquired Bacterial Pneumonia...

1 month ago - GlobeNewsWire

Lefamulin Receives Approval in Taiwan for Treatment of Community-Acquired Pneumonia

DUBLIN, Ireland and FORT WASHINGTON, Pa., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of inno...

1 month ago - GlobeNewsWire

Nabriva Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

DUBLIN, Ireland, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective age...

1 month ago - GlobeNewsWire

Nabriva Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

DUBLIN, Ireland and FORT WASHINGTON, Pa., Aug. 31, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innov...

1 month ago - GlobeNewsWire

Nabriva Therapeutics Reports Second Quarter 2021 Financial Results and Provides a Corporate Update

-Revenues of $8.2 million driven by launch of own National Drug Code (NDC) for SIVEXTRO-

2 months ago - GlobeNewsWire

Nabriva Therapeutics to Report Second Quarter 2021 Financial Results and Recent Corporate Highlights on August 5, 2021

DUBLIN, Ireland, July 22, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agen...

3 months ago - GlobeNewsWire

Down 15.7% in 4 Weeks, Here's Why You Should You Buy the Dip in Nabriva Therapeutics AG (NBRV)

Nabriva Therapeutics AG (NBRV) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnin...

3 months ago - Zacks Investment Research

Nabriva Agrees to Extension of Principal Debt Repayments Under Existing Loan Agreement with Hercules Capital

- Principal Repayments Delayed At Least Until January 1, 2022

4 months ago - GlobeNewsWire

Nabriva Announces Changes to its Board of Directors

DUBLIN, Ireland and FORT WASHINGTON, Pa., June 02, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innov...

4 months ago - GlobeNewsWire

Nabriva Therapeutics Stock Gains On Positive Lefamulin Data In CABP Patients In China

Nabriva Therapeutics (NASDAQ: NBRV) and its collaborating partner in China, Sinovant Sciences, have announced positive topline results from Sinovant's Phase 3 bridging study evaluating lefamulin in Chin...

4 months ago - Benzinga

Sinovant Sciences and Nabriva Therapeutics Announce Positive Topline Results from Phase 3 Trial of Lefamulin in Chine...

HONG KONG, SHANGHAI, China, SUZHOU, China and DUBLIN, Ireland, May 25, 2021 (GLOBE NEWSWIRE) -- Sinovant Sciences, a Chinese biopharmaceutical company dedicated to conducting innovative biomedical R&D i...

4 months ago - GlobeNewsWire

Nabriva Therapeutics to Present at the Jefferies Virtual Healthcare Conference

DUBLIN, Ireland and KING OF PRUSSIA, Pa., May 21, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innova...

5 months ago - GlobeNewsWire

Nabriva Therapeutics Reports First Quarter 2021 Financial Results and Provides Corporate Updates

-First quarter of full complement of 60 sales representatives further expanding the reach of XENLETA ® (lefamulin) and SIVEXTRO ® (tedizolid phosphate) in the community-

5 months ago - GlobeNewsWire

Nabriva Therapeutics to Report First Quarter 2021 Financial Results and Recent Corporate Highlights on May 6, 2021

DUBLIN, Ireland, April 29, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective age...

5 months ago - GlobeNewsWire

Rising P/E: An Overlooked Way to Pick 5 Winning Stocks

Want to try an out-of-the-box approach? Tap five stocks with increasing P/E ratios.

Other symbols:ALYACPRTCRDFLQDA
5 months ago - Zacks Investment Research

Nabriva Commences Exclusive Distribution of SIVEXTRO® (tedizolid phosphate) in the U.S.

- SIVEXTRO now available under Nabriva's National Drug Code

6 months ago - GlobeNewsWire

Rising P/E: An Overlooked Strategy to Pick Winning Stocks

Want to try an out-of-the-box approach? Tap five stocks with increasing P/E ratios.

Other symbols:ADBECRDFKNSLVEEV
6 months ago - Zacks Investment Research